Hyundai Pharmaceutical Co (XKRX:004310) EV-to-EBIT : 31.69 (As of Sep. 22, 2024)

Hyundai Pharmaceutical Co EV-to-EBIT Chart

Hyundai Pharmaceutical Co Annual Data
	Trend	Nov14	Nov15	Nov16	Nov17	Nov18	Nov19	Nov20	Nov21	Nov22	Nov23
EV-to-EBIT		Get a 7-Day Free Trial					69.32	56.06	-43.86	20.25	12.66

Hyundai Pharmaceutical Co Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
EV-to-EBIT	Get a 7-Day Free Trial															19.14	19.94	12.66	18.08	25.43

Competitive Comparison of Hyundai Pharmaceutical Co's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hyundai Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyundai Pharmaceutical Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hyundai Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hyundai Pharmaceutical Co's EV-to-EBIT falls into.

Hyundai Pharmaceutical Co EV-to-EBIT Calculation

Hyundai Pharmaceutical Co's EV-to-EBIT for today is calculated as:

Hyundai Pharmaceutical Co's current Enterprise Value is ₩154,010 Mil.
Hyundai Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,859 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyundai Pharmaceutical Co  (XKRX:004310) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hyundai Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in May. 2024 is calculated as:

Hyundai Pharmaceutical Co's Enterprise Value for the quarter that ended in May. 2024 was ₩123,562 Mil.
Hyundai Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩4,859 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyundai Pharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hyundai Pharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyundai Pharmaceutical Co Business Description